NCCN

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.

The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.

The network said MDxHealth's ConfirmMDx should be used to screen men at higher risk for prostate cancer despite a negative biopsy. 

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has included two molecular diagnostics – Myriad Genetics' Prolaris and Genomic Health's Oncotype DX Prostate Cancer – in its most recent guidelines for the disease, noting that these two assays "appear further along in development a

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has approved inclusion of Biodesix's VeriStrat proteomics test in its guidelines for non-small cell lung cancer, the Boulder, Colo.-based firm said today.

The National Comprehensive Cancer Network now supports MGMT methylation testing in elderly glioblastoma patients to assess the likelihood that they will benefit from temozolomide treatment. This may help spur adoption of MDxHealth's MGMT PredictMDx for Glioblastoma test.

This article has been updated to correct that Ellen Matloff is a plaintiff in AMP v. USPTO.

After garnering a CLIA-certified clinical laboratory through its purchase of Navigenics last week, Life Technologies wasted no time jumping into the molecular diagnostics space.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.